Navigation Links
Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference

PRINCETON, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the 28th Annual JPMorgan Healthcare Conference being held from January 11 to 14, 2010 at the Westin St Francis in San Francisco, CA. Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company at the conference on Thursday, January 14, 2010 at 2:00 PM (PT).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infection, is in a Phase 2b clinical trial in combination with Pegasys® plus Copegus® and is also in the phase 1b INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates include PSI-7851, an unpartnered, next generation HCV nucleotide analog, that has completed initial Phase 1 clinical studies which provided supportive safety and efficacy data to initiate a Phase 2a trial in 1Q 2010 and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial. We have also recently announced the nomination of two purine nucleotide analogs, PSI-938 and PSI-879, for preclinical development.

Pegasys® and Copegus® are registered trademarks of Roche.

    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of

1995: Statements in this press release regarding our business that are not historical facts are

"forward-looking statements" that involve risks and uncertainties, including, without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these and other risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2009 and filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

SOURCE Pharmasset, Inc.



SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Reports Fiscal Year End 2009 Financial Results
2. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
3. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
5. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
6. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
7. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
8. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
9. Pharmasset Reports Fiscal Year End 2008 Financial Results
10. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
11. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
Post Your Comments:
(Date:10/13/2015)... , October 13, 2015 ... World Thrombosis Day Interactive Infographic   --> ... World Thrombosis Day  to promote vital global awareness ... and symptoms. Thrombosis is the formation of potentially ... - resulting in venous thromboembolism (VTE) - or the ...
(Date:10/12/2015)... Given the intricacy of the anatomy and physiology of ... drug effectively to a specific ocular site. Several barriers have ... include dilution of a drug by tears, clearance of a ... issues with respect to the cornea, sclera and choroid. Approximately ... due to the aforementioned barriers. --> Given ...
(Date:10/12/2015)... 12, 2015  The Pharmacy Compounding Accreditation Board ... Pharmacy in Costa Mesa , ... the pharmacy,s commitment to meeting and/or exceeding national ... --> --> ... --> --> Harbor Compounding ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... ... Symposium Chairman, Dr. Rod J. Rohrich is pleased to announce that registration ... 2nd and 3rd, 2016. The annual meeting, along with the Dallas Rhinoplasty ... the world. , Key topics at this year's event will include discussions on efficacy ...
(Date:10/13/2015)... ... October 13, 2015 , ... e-con Systems Inc., a ... announced See3CAM_CU40, the industry’s first RGB-IR pixel format camera with a USB ... member of e-con’s See3CAM family of UVC USB 3.0 cameras, is based on the ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec ... their Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference will ... Ranch and will unite customers, partners, WennSoft team members and sponsors to facilitate ...
(Date:10/13/2015)... ... October 13, 2015 , ... Tempe Dental Care, a leading Tempe dentists’ office, ... IV sedation dentistry for more than 5 years. A leading cause of emergency ... painful if treatment is not timely. , Sedation dentistry provides an ...
(Date:10/13/2015)... ... October 13, 2015 , ... Breathing is ... do not breathe correctly. According to T’ai Chi (also spelled “Taiji”) and Qigong ... breathe correctly, in concert with the 7,000 year old tradition they teach, can ...
Breaking Medicine News(10 mins):